415 related articles for article (PubMed ID: 28893800)
1.
Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P
Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800
[TBL] [Abstract][Full Text] [Related]
2. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
5. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
6. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
7. Modeling Renal Cell Carcinoma in Mice:
Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
[TBL] [Abstract][Full Text] [Related]
8. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
9. Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma.
Ricketts CJ; Linehan WM
Cancer Discov; 2017 Nov; 7(11):1221-1223. PubMed ID: 29097620
[TBL] [Abstract][Full Text] [Related]
10. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
[TBL] [Abstract][Full Text] [Related]
11. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.
Ding Z; German P; Bai S; Reddy AS; Liu XD; Sun M; Zhou L; Chen X; Zhao X; Wu C; Zhang S; Mills GB; Jonasch E
Cancer Res; 2014 Jun; 74(11):3127-36. PubMed ID: 24755468
[TBL] [Abstract][Full Text] [Related]
12. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
[TBL] [Abstract][Full Text] [Related]
13. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
14. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
16. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
17. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
20. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]